Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6.

Qie S, Diehl JA.

Mol Cell Oncol. 2019 May 7;6(4):1610257. doi: 10.1080/23723556.2019.1610257. eCollection 2019.

PMID:
31211239
2.

The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells.

Gui J, Katlinski KV, Koumenis C, Diehl JA, Fuchs SY.

Mol Cancer Res. 2019 Mar 22. doi: 10.1158/1541-7786.MCR-19-0002. [Epub ahead of print]

PMID:
30902831
3.

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.

Qie S, Yoshida A, Parnham S, Oleinik N, Beeson GC, Beeson CC, Ogretmen B, Bass AJ, Wong KK, Rustgi AK, Diehl JA.

Nat Commun. 2019 Mar 21;10(1):1296. doi: 10.1038/s41467-019-09179-w.

4.

Inhibition of the PERK-Dependent Unfolded Protein Response Signaling Pathway Involved in the Pathogenesis of Alzheimer's Disease.

Rozpędek W, Pytel D, Popławski T, Walczak A, Gradzik K, Wawrzynkiewicz A, Wojtczak R, Mucha B, Diehl JA, Majsterek I.

Curr Alzheimer Res. 2019;16(3):209-218. doi: 10.2174/1567205016666190228121157.

PMID:
30819079
5.
6.

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY.

Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001.

PMID:
30645975
7.

Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.

Kijima T, Nakagawa H, Shimonosono M, Chandramouleeswaran PM, Hara T, Sahu V, Kasagi Y, Kikuchi O, Tanaka K, Giroux V, Muir AB, Whelan KA, Ohashi S, Naganuma S, Klein-Szanto AJ, Shinden Y, Sasaki K, Omoto I, Kita Y, Muto M, Bass AJ, Diehl JA, Ginsberg GG, Doki Y, Mori M, Uchikado Y, Arigami T, Avadhani NG, Basu D, Rustgi AK, Natsugoe S.

Cell Mol Gastroenterol Hepatol. 2018 Sep 14;7(1):73-91. doi: 10.1016/j.jcmgh.2018.09.003. eCollection 2019.

8.

Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.

Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9298-E9307. doi: 10.1073/pnas.1807704115. Epub 2018 Sep 17.

9.

Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.

Wong GS, Zhou J, Bin Liu J, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ.

Nat Med. 2018 Oct;24(10):1627. doi: 10.1038/s41591-018-0168-6.

PMID:
30093730
10.

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.

Adeegbe DO, Liu S, Hattersley MM, Bowden M, Zhou CW, Li S, Vlahos R, Grondine M, Dolgalev I, Ivanova EV, Quinn MM, Gao P, Hammerman PS, Bradner JE, Diehl JA, Rustgi AK, Bass AJ, Tsirigos A, Freeman GJ, Chen H, Wong KK.

Cancer Immunol Res. 2018 Oct;6(10):1234-1245. doi: 10.1158/2326-6066.CIR-18-0077. Epub 2018 Aug 7.

PMID:
30087114
11.

IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.

Karakasheva TA, Lin EW, Tang Q, Qiao E, Waldron TJ, Soni M, Klein-Szanto AJ, Sahu V, Basu D, Ohashi S, Baba K, Giaccone ZT, Walker SR, Frank DA, Wileyto EP, Long Q, Dunagin MC, Raj A, Diehl JA, Wong KK, Bass AJ, Rustgi AK.

Cancer Res. 2018 Sep 1;78(17):4957-4970. doi: 10.1158/0008-5472.CAN-17-2268. Epub 2018 Jul 5.

PMID:
29976575
12.

Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.

Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ.

Nat Med. 2018 Jul;24(7):968-977. doi: 10.1038/s41591-018-0022-x. Epub 2018 May 28. Erratum in: Nat Med. 2018 Oct;24(10):1627.

13.

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.

de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, Li Z, Cheng LC, Yoshida A, Courtney SM, Hazard ES, Hardiman G, Hussain MH, Diehl JA, Drake JM, Kelly WK, Knudsen KE.

Clin Cancer Res. 2018 Sep 1;24(17):4201-4214. doi: 10.1158/1078-0432.CCR-18-0410. Epub 2018 May 8.

PMID:
29739788
14.

The Long (lncRNA) and Short (miRNA) of It: TGFβ-Mediated Control of RNA-Binding Proteins and Noncoding RNAs.

Janakiraman H, House RP, Gangaraju VK, Diehl JA, Howe PH, Palanisamy V.

Mol Cancer Res. 2018 Apr;16(4):567-579. doi: 10.1158/1541-7786.MCR-17-0547. Epub 2018 Mar 19. Review.

15.

Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.

Rozpędek W, Pytel D, Nowak-Zduńczyk A, Lewko D, Wojtczak R, Diehl JA, Majsterek I.

Curr Med Chem. 2019;26(8):1425-1445. doi: 10.2174/0929867325666180117102233. Review.

PMID:
29345572
16.

A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival.

Bu Y, Yoshida A, Chitnis N, Altman BJ, Tameire F, Oran A, Gennaro V, Armeson KE, McMahon SB, Wertheim GB, Dang CV, Ruggero D, Koumenis C, Fuchs SY, Diehl JA.

Nat Cell Biol. 2018 Jan;20(1):104-115. doi: 10.1038/s41556-017-0006-y. Epub 2017 Dec 11.

17.

Addendum: A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression.

Grelet S, Link LA, Howley B, Obellianne C, Palanisamy V, Gangaraju VK, Diehl JA, Howe PH.

Nat Cell Biol. 2017 Nov 29;19(12):1443. doi: 10.1038/ncb3647.

PMID:
29184176
18.

Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma.

Natsuizaka M, Whelan KA, Kagawa S, Tanaka K, Giroux V, Chandramouleeswaran PM, Long A, Sahu V, Darling DS, Que J, Yang Y, Katz JP, Wileyto EP, Basu D, Kita Y, Natsugoe S, Naganuma S, Klein-Szanto AJ, Diehl JA, Bass AJ, Wong KK, Rustgi AK, Nakagawa H.

Nat Commun. 2017 Nov 24;8(1):1758. doi: 10.1038/s41467-017-01500-9.

19.

Recent insights into PERK-dependent signaling from the stressed endoplasmic reticulum.

McQuiston A, Diehl JA.

F1000Res. 2017 Oct 27;6:1897. doi: 10.12688/f1000research.12138.1. eCollection 2017. Review.

20.

Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.

Qie S, Majumder M, Mackiewicz K, Howley BV, Peterson YK, Howe PH, Palanisamy V, Diehl JA.

Nat Commun. 2017 Nov 16;8(1):1534. doi: 10.1038/s41467-017-01199-8.

21.

CNPY2 is a key initiator of the PERK-CHOP pathway of the unfolded protein response.

Hong F, Liu B, Wu BX, Morreall J, Roth B, Davies C, Sun S, Diehl JA, Li Z.

Nat Struct Mol Biol. 2017 Oct;24(10):834-839. doi: 10.1038/nsmb.3458. Epub 2017 Sep 4.

22.

A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression.

Grelet S, Link LA, Howley B, Obellianne C, Palanisamy V, Gangaraju VK, Diehl JA, Howe PH.

Nat Cell Biol. 2017 Sep;19(9):1105-1115. doi: 10.1038/ncb3595. Epub 2017 Aug 21. Erratum in: Nat Cell Biol. 2017 Nov 29;19(12 ):1443.

23.

Inhibition of PERK-dependent pro-adaptive signaling pathway as a promising approach for cancer treatment.

Rozpędek W, Pytel D, Dziki Ł, Nowak A, Dziki A, Diehl JA, Majsterek I.

Pol Przegl Chir. 2017 Jun 30;89(3):7-10.

24.

Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.

Noguchi K, Dalton AC, Howley BV, McCall BJ, Yoshida A, Diehl JA, Howe PH.

PLoS One. 2017 May 17;12(5):e0177830. doi: 10.1371/journal.pone.0177830. eCollection 2017.

25.

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Zhang H, Fillmore Brainson C, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Diehl JA, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.

Nat Commun. 2017 Apr 7;8:14922. doi: 10.1038/ncomms14922. Erratum in: Nat Commun. 2017 Jun 09;8:15901.

26.

Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways.

Rozpedek W, Nowak A, Pytel D, Diehl JA, Majsterek I.

Curr Mol Med. 2017;17(2):118-132. doi: 10.2174/1566524017666170306122643. Review.

PMID:
28266275
27.

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY.

Cancer Cell. 2017 Feb 13;31(2):194-207. doi: 10.1016/j.ccell.2017.01.004.

28.

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.

Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, Xu X, Sicinska E, Sanchez-Vega F, Rustgi AK, Diehl JA, Wong KK, Bass AJ.

Nat Commun. 2017 Jan 6;8:13897. doi: 10.1038/ncomms13897.

29.

HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation.

Gannon PJ, Akay-Espinoza C, Yee AC, Briand LA, Erickson MA, Gelman BB, Gao Y, Haughey NJ, Zink MC, Clements JE, Kim NS, Van De Walle G, Jensen BK, Vassar R, Pierce RC, Gill AJ, Kolson DL, Diehl JA, Mankowski JL, Jordan-Sciutto KL.

Am J Pathol. 2017 Jan;187(1):91-109. doi: 10.1016/j.ajpath.2016.09.006.

30.

PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.

Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA.

PLoS Genet. 2016 Dec 15;12(12):e1006518. doi: 10.1371/journal.pgen.1006518. eCollection 2016 Dec.

31.

Correction: RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC.

Majumder M, House R, Palanisamy N, Qie S, Day TA, Neskey D, Diehl JA, Palanisamy V.

PLoS Genet. 2016 Oct 26;12(10):e1006411. doi: 10.1371/journal.pgen.1006411. eCollection 2016 Oct.

32.

[Small molecule inhibitors of PERK-dependent signaling pathway as a novel, therapeutic molecular strategy in Alzheimer's disease treatment].

Rozpędek W, Pytel D, Diehl JA, Majsterek I.

Pol Merkur Lekarski. 2016 Jul 29;41(241):5-10. Review. Polish.

PMID:
27734813
33.

Cyclin D3: To translate or not to translate.

Diehl JA.

Cell Cycle. 2016 Nov 16;15(22):3018-3019. Epub 2016 Aug 11. No abstract available.

34.

Cyclin D1, cancer progression, and opportunities in cancer treatment.

Qie S, Diehl JA.

J Mol Med (Berl). 2016 Dec;94(12):1313-1326. Epub 2016 Oct 2. Review.

35.

RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC.

Majumder M, House R, Palanisamy N, Qie S, Day TA, Neskey D, Diehl JA, Palanisamy V.

PLoS Genet. 2016 Sep 8;12(9):e1006306. doi: 10.1371/journal.pgen.1006306. eCollection 2016 Sep. Erratum in: PLoS Genet. 2016 Oct 26;12 (10 ):e1006411.

36.

Stressing out melanoma with an anti-GRP78 compound.

Bu Y, Diehl JA.

Pigment Cell Melanoma Res. 2016 Sep;29(5):490-1. doi: 10.1111/pcmr.12499. Epub 2016 Aug 3. No abstract available.

37.

The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress.

Rozpedek W, Pytel D, Mucha B, Leszczynska H, Diehl JA, Majsterek I.

Curr Mol Med. 2016;16(6):533-44. Review.

38.

miR-216b regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis.

Xu Z, Bu Y, Chitnis N, Koumenis C, Fuchs SY, Diehl JA.

Nat Commun. 2016 May 13;7:11422. doi: 10.1038/ncomms11422.

39.

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY.

Cell Rep. 2016 Apr 5;15(1):171-180. doi: 10.1016/j.celrep.2016.03.006. Epub 2016 Mar 24.

40.

Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria.

Cárdenas C, Müller M, McNeal A, Lovy A, Jaňa F, Bustos G, Urra F, Smith N, Molgó J, Diehl JA, Ridky TW, Foskett JK.

Cell Rep. 2016 Apr 5;15(1):219-220. doi: 10.1016/j.celrep.2016.03.045. No abstract available.

41.

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.

Yoshida A, Lee EK, Diehl JA.

Cancer Res. 2016 May 15;76(10):2990-3002. doi: 10.1158/0008-5472.CAN-15-2931. Epub 2016 Mar 17.

42.

Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria.

Cárdenas C, Müller M, McNeal A, Lovy A, Jaňa F, Bustos G, Urra F, Smith N, Molgó J, Diehl JA, Ridky TW, Foskett JK.

Cell Rep. 2016 Mar 15;14(10):2313-24. doi: 10.1016/j.celrep.2016.02.030. Epub 2016 Mar 3. Erratum in: Cell Rep. 2016 Apr 5;15(1):219-20.

43.

PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development.

Bu Y, Diehl JA.

J Cell Physiol. 2016 Oct;231(10):2088-96. doi: 10.1002/jcp.25336. Epub 2016 Mar 6. Review.

44.

[The role of the adaptive stress response in the pathogenesis of neurodegenerative diseases, cancer and diabetes mellitus type 2].

Rozpędek W, Markiewicz Ł, Diehl JA, Pytel D, Majsterek I.

Pol Merkur Lekarski. 2015 Dec;39(234):393-7. Review. Polish.

PMID:
26802695
45.

CDK4/6 inhibitor: from quiescence to senescence.

Yoshida A, Diehl JA.

Oncoscience. 2015 Oct 20;2(11):896-7. eCollection 2015. No abstract available.

46.

Type I interferons mediate pancreatic toxicities of PERK inhibition.

Yu Q, Zhao B, Gui J, Katlinski KV, Brice A, Gao Y, Li C, Kushner JA, Koumenis C, Diehl JA, Fuchs SY.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15420-5. doi: 10.1073/pnas.1516362112. Epub 2015 Dec 1.

47.

PRMT5-dependent p53 escape in tumorigenesis.

Li Y, Diehl JA.

Oncoscience. 2015 Aug 31;2(8):700-2. eCollection 2015.

48.

Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease.

Rozpedek W, Markiewicz L, Diehl JA, Pytel D, Majsterek I.

Curr Med Chem. 2015;22(27):3169-84. Review.

49.

Ultrasonographic Median Nerve Changes After Repeated Wheelchair Transfers in Persons With Paraplegia: Relationship With Subject Characteristics and Transfer Skills.

Hogaboom NS, Diehl JA, Oyster ML, Koontz AM, Boninger ML.

PM R. 2016 Apr;8(4):305-313. doi: 10.1016/j.pmrj.2015.08.001. Epub 2015 Aug 8.

PMID:
26265431
50.

Tumor progression and the different faces of the PERK kinase.

Pytel D, Majsterek I, Diehl JA.

Oncogene. 2016 Mar 10;35(10):1207-15. doi: 10.1038/onc.2015.178. Epub 2015 Jun 1. Review.

Supplemental Content

Loading ...
Support Center